CTT Pharma Signs LOI for Clinical Trials and Testing of Nicotine Products

Rhea-AI Summary

CTT Pharma (OTCQB:CTTH) signed a letter of intent with a U.S. testing company to conduct clinical trials and testing for several potential nicotine products using its patented technology.

The arrangement could support independent U.S. market entry, with further updates to be provided to shareholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TAMPA, FL / ACCESS Newswire / June 22, 2026 / CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) has signed an LOI with a testing company in the United States to conduct clinical trials and testing for several potential nicotine products for CTT Pharma. A partnership with this company would allow CTT the ability to independently go to market in the United States utilizing our patented technology. CTT Pharma will notify shareholders as more information becomes available.

About CTT Pharmaceutical Holdings, Inc.

CTT Pharmaceutical Holdings, Inc. is a pharmaceutical technology company specializing in the development and commercialization of thin film oral drug delivery systems designed to provide rapid onset, enhanced patient convenience, and efficient absorption. The Company's patented micelle based thin film platform is intended to offer a novel alternative to traditional dosage forms across pharmaceutical, therapeutic, and nutraceutical markets. CTT is focused on integrating scientific validation, scalable manufacturing, and regulatory preparedness to support long-term growth and product innovation.

Forward-Looking Statements

Forward-looking statements include statements regarding the Company's plans, objectives, expectations, and intentions, including potential future business operations. Words such as anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, should, will, would and similar expressions identify forward-looking statements. These statements are based on management's current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Important factors that could cause such differences include, but are not limited to: the timing and outcome of a potential partnership. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

CTT Pharmaceutical Holdings, Inc.
813-606-0060

SOURCE: CTT Pharmaceutical Holdings, Inc.

View the original press release on ACCESS Newswire

FAQ

What did CTT Pharma (OTCQB:CTTH) announce on June 22, 2026 about nicotine products?

CTT Pharma announced it signed a letter of intent for clinical trials and testing of potential nicotine products. According to CTT Pharma, the LOI is with a U.S. testing company and covers several nicotine product candidates that would use the company’s patented technology.

What is the purpose of CTT Pharma’s LOI for nicotine clinical trials and testing (CTTH)?

The LOI aims to enable clinical trials and testing of several potential nicotine products for CTT Pharma. According to CTT Pharma, working with the U.S. testing company supports the development and assessment of products that could later use the company’s patented delivery technology.

How could the nicotine clinical testing LOI affect CTT Pharma’s U.S. market plans (CTTH)?

The LOI could help CTT Pharma move toward independently entering the U.S. nicotine market. According to CTT Pharma, partnering with the testing company would allow commercialization using its patented technology if development progresses and future requirements for market entry are met.

What role does CTT Pharma’s patented technology play in the new nicotine LOI (CTTH)?

CTT Pharma’s patented technology is intended for use in the potential nicotine products under evaluation. According to CTT Pharma, the partnership with the U.S. testing company could enable future independent commercialization in the United States using this technology, subject to successful trials and other necessary steps.

What information will CTT Pharma shareholders receive about the nicotine clinical trials LOI (CTTH)?

Shareholders will be updated as more information about the nicotine clinical trials and testing becomes available. According to CTT Pharma, it plans to notify investors about future developments related to the LOI, product testing progress, and any potential implications for market entry in the United States.

Is the agreement between CTT Pharma and the U.S. testing company for nicotine products final (CTTH)?

CTT Pharma has signed a letter of intent, which is a preliminary, non-final agreement. According to CTT Pharma, the LOI outlines cooperation on clinical trials and testing, and the company will provide further details to shareholders as the relationship and plans progress.